Mesoblast Limited is a biopharmaceutical company specializing in the development and commercialization of innovative allogeneic cellular medicines. These therapies are derived from mesenchymal lineage cells collected from the bone marrow of healthy adult donors. The company utilizes proprietary processes to expand these cells into a uniform and highly reproducible population, which can respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. Mesoblast's core product candidates are in Phase 3 clinical trials and target conditions such as steroid-refractory acute graft versus host disease (acute GVHD), moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, and advanced chronic heart failure. The company operates in the global biopharmaceutical market, serving patients with significant unmet medical needs. Mesoblast generates revenue through the development and commercialization of its proprietary cellular medicines, as well as through partnerships and licensing agreements.

Keywords: allogeneic cellular medicines, mesenchymal lineage cells, tissue repair, immune modulation, acute GVHD, ARDS, chronic heart failure, biopharmaceutical, proprietary technology, clinical trials.